VALUE OF NICOTINIC ACID IN THE CURRENT CARDIOLOGY
https://doi.org/10.20996/1819-6446-2011-7-3-365-370
Abstract
Statin intake is a standard in the treatment of patients with atherosclerosis nowadays. These drugs therapy associates with 30% risk reduction in mortality and coronary events. However , the threat of recurrent events is sufficiently high in large part of patients. This can be related to low level of high density lipoprotein cholesterol as well as elevated levels of triglycerides and lipoprotein(a). Nicotinic acid intake in these patients may be necessary for the normalization of lipid profile, including lipoprotein(a), and will be able to reduce residual cardiovascular risk. Evidence-based medicine data are presented to prove an efficacy of nicotinic acid in high doses in cardiology practice. Nicotinic acid both in monotherapy and in combination with statins contributes to coronary and carotid atherosclerosis regression and reduces an incidence of cardiovascular complications. Long-acting formulation of nicotinic acid, correct receiving regime and blood bio-chemical monitoring contribute to long-term safety of the drug in patients with clinically significant atherosclerosis.
About the Authors
E. P. Trukhacheva
Russian Cardiology Research and Production Complex
Russian Federation
Russian Federation
M. V. Ezhov
Russian Cardiology Research and Production Complex
Russian Federation
Russian Federation
References
1. Boden W.E., O'Rourke R.A., Teo K.K. et al. COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007; 356: 1503-1516
2. The AIM-HIGH Investigators The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: Rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes. Am Heart J 2011;161:471-477.
3. Nordestgaard B.G., Chapman M.J., Ray K. et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010;31(23):2844-2853.
4. Altschul R., Herman I.H. Influence of oxygen inhalation on cholesterol metabolism. Arch Biochem 1954; 51: 308–9.
5. Parsons W.B. Jr., Achor R.W., Berge K.G. et al. Changes in blood lipids following prolonged administration of large doses of nicotinic acid to persons with hypercholesterolemia. Proc Mayo Clin 1956;31(13): 377.
6. Parsons W.B., Flinn J.H. Reduction of serum cholesterol levels and beta-lipoprotecholesterol levels by nicotinic acid. Arch Intern Med 1959; 103: 783–90.
7. Kamanna V.S., Kashyap M.L. Mechanism of action of niacin. Am J Cardiol 2008;101(8A):20B-26B.
8. McKenney J. New perspectives on the use of niacin in the treatment of lipid disorders. Arch Intern Med 2004; 164: 697-705.
9. Taubert K., Mosca L., Pasternak R.S. et al. AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update. Circulation 2006;113: 2363-2372.
10. Stamler J. The coronary drug project--findings with regard to estrogen, dextrothyroxine, clofibrate and niacin. Adv Exp Med Biol 1977;82:52-75.
11. Canner P.L., Berge K.G., Wenger N.K. et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986; 8: 1245-1255.
12. Blankenhorn D.H., Nessim S.A., Johnson R.L. et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987;257:3233-40.
13. Azen S.P., Mack W.J., Cashin-Hemphill L. et al. Progression of coronary artery disease predicts clinical coronary. Events long-term follow-up from the Cholesterol Lowering Atherosclerosis Study. Circulation 1996; 93:34-41.
14. Brown B.G., Zhao X.Q., Chait A. et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease, the HDL-Atherosclerosis Treatment Study (HATS). N Engl J Med 2001; 345: 1583–92.
15. Taylor A.J., Sullenberger L.E., Lee H.J. et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004;110:3512-3517
16. Taylor A.J., Lee H.J., Sullenberger L.E. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin 2006;22:2243-2250.
17. Taylor A.J., Villines T.C., Stanek E.J. et al. Extended-Release Niacin or Ezetimibe and Carotid Intima-Media Thickness. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6—HDL and LDL Treatment Strategies (ARBITER 6—HALTS). N Engl J Med 2009;361:2113-22.
18. Bruckert E., Labreuche J., Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 2010;210(2):353-61.
19. Biasucci L.M. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease. Application to clinical and public health practice: clinical use of inflammatory markers in patients with cardiovascular diseases: a background paper. Circulation 2004;110:e560-e567.
20. Kuvin J.T., Dave D.M., Sliney K.A. et al. Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. Am J Cardiol 2006;98:743-5.
21. Kashyap M.L., McGovern M.E., Berra K. et al. Long-Term safety and efficacy of a once-daily Niacin/Lo-vastatin formulation for patients with dyslipidemia. Am J Cardiol 2002; 89: 672-678.
22. Grundy S.M., Vega G.L., McGovern M.E. et al. Efficacy, safety and tolerability of once-daily niacin therapy for the treatment of dyslipidemia associated with type 2 diabetes: results of assessment of diabetes control and evaluation of efficacy of Niaspan trial. Arch Intern Med 2002; 162: 1568-1576.
23. Weiner M., Redisch W., Steele J.M. Occurrence of fibrinolytic activity following administration of nicotinic acid. Proc Soc Exp Biol Med 1958; 98: 755–757.
24. Brown S.L., Sobel B.E., Fujii S. Attenuation of the Synthesis of Plasminogen Activator Inhibitor Type 1 by Niacin. Circulation 1995;92:767-772.
25. Hamsten A., de Faire U., Walldius G. et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987;2: 3–9.
26. Johansson J.O., Egberg N., Asplund-Carlson A. et al. Nicotinic acid treatment shifts the fibrinolytic balance favourably and decreases plasma fibrinogen in hypertriglyceridaemic men. J Cardiovasc Risk 1997;4:165–171.
27. Chesney C.M., Elam M.B., Herd J.A. et al. Effect of niacin, warfarin, and antioxidant therapy on coagulation parameters in patients with peripheral arterial disease in the Arterial Disease Multiple Intervention Trial (ADMIT). Am Heart J 2000;140: 631–6.
28. Oganov R.G., Kiseleva N.G., Aronov D.M. et al. The use of Enduracin--a prolonged-action form of nicotinic acid--in correcting atherogenic dyslipidemias. Kardiologiia 1993;33(10):54-9, 6. Russian (Оганов Р.Г., Киселева Н.Г., Аронов Д.М. и др. Применение эндурацина, пролонгированной формы никотиновой кислоты, в коррекции атерогенной дислипидемии. Кардиология 1993;10:54-59).
29. Cheng K., Wu T.J., Wu K.K. et al. Antagonism of the prostaglandin D2 receptor 1 supresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci USA 2006; 103:6682-6687.
30. Cefali E.A., Simmons P.D., Stanek E.J. et al. Aspirin reduces cutaneous flushing after administration of an optimized extended-release niacin formulation. Int J Clin Pharmaloc Ther 2007;45:78-88.
31. National guidelines for diagnosis and correction of disorders of lipid metabolism in order to prevent and treat atherosclerosis. Kardiovaskulyarnaya terapiya i profilaktika, 2009; 8(6) suppl 3: 1-32. Russian (Национальные рекомендации по диагностике и коррекции нарушений липидного обмена с целью профилактики и лечения атеросклероза. Кардиоваскулярная терапия и профилактика, 2009; 8(6) Приложение 3: 1-32).
32. Ballantyne C.M., Davidson M.H., McKenney J. et al. Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non–HDL cholesterol: from the SEACOAST I study. Am J Cardiol 2008;101:1428–143.
33. Ballantyne C.M., Davidson M.H., McKenny J.M. et al. Comparison of the efficacy and safety of a combination tablet of niacin extended-release and simvastatin with simvastatin 80 mg monotherapy: the SEACOAST II (high-dose) study. J Clin Lipid 2008;2:79-90.
34. Karas R.H., Kashyap M.L., Knopp R.H. et al. Long-term safety and efficacy of a combination of niacin extended release andsimvastatin in patients with dyslipidemia: the OCEANS study. Am J Cardiovasc Drugs 2008;8(2):69-81.
35. McKenney J.M., Jones P.H., Bays H.E. et al. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). Atherosclerosis 2007; 192: 432-437.
36. Harikrishnan S., Rajeev E., Tharakan J.A. et al. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol. Indian Heart J 2008;60(3): 215-222.
Review
For citations:
Trukhacheva E.P., Ezhov M.V. VALUE OF NICOTINIC ACID IN THE CURRENT CARDIOLOGY. Rational Pharmacotherapy in Cardiology. 2011;7(3):365-370. (In Russ.) https://doi.org/10.20996/1819-6446-2011-7-3-365-370
Views:
1045
.jpg)
Email this article 